Delphine L. Chen
YOU?
Author Swipe
View article: Consistent performance between medical experts and non‐expert readers in forced‐choice lesion‐detection tasks with PET images
Consistent performance between medical experts and non‐expert readers in forced‐choice lesion‐detection tasks with PET images Open
Background Labeled data are used to train, validate, and test deep learning model observers (DLMOs) as well as linear model observers, such as channelized Hotelling observers (CHOs), for image quality assessment in many imaging modalities,…
View article: [18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer Open
Aim This study examines the combination of FES-PET and FDG-PET as complementary imaging for detection of metastatic ILC. Methods We retrospectively evaluated FES and FDG uptake in patients with metastatic ILC from an estrogen receptor (ER)…
View article: Thorax‐encompassing multi‐modality PET/CT deep learning model for resected lung cancer prognostication: A retrospective, multicenter study
Thorax‐encompassing multi‐modality PET/CT deep learning model for resected lung cancer prognostication: A retrospective, multicenter study Open
Background Patients with early‐stage non‐small cell lung cancer (NSCLC) typically receive surgery as their primary form of treatment. However, studies have shown that a high proportion of these patients will experience a recurrence after t…
View article: Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer Open
Background 18 F-Fluorodeoxyglucose (FDG) and 18 F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging f…
View article: Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions Open
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining ev…
View article: Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer Open
Background 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomogr…
View article: PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177</sup>Lu-PSMA-617: Importance of<sup>18</sup>F-FDG–Avid Discordant Findings
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received<sup>177</sup>Lu-PSMA-617: Importance of<sup>18</sup>F-FDG–Avid Discordant Findings Open
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION a…
View article: SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving<sup>177</sup>Lu-PSMA-617
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving<sup>177</sup>Lu-PSMA-617 Open
177Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study …
View article: A deep learning anthropomorphic model observer for a detection task in PET
A deep learning anthropomorphic model observer for a detection task in PET Open
Background Lesion detection is one of the most important clinical tasks in positron emission tomography (PET) for oncology. An anthropomorphic model observer (MO) designed to replicate human observers (HOs) in a detection task is an import…
View article: Unmasking hidden Merkel cell carcinoma recurrences: Three illustrative cases of patients with rising viral oncoprotein antibody levels and challenge of requiring multi-modal imaging to detect clinical disease
Unmasking hidden Merkel cell carcinoma recurrences: Three illustrative cases of patients with rising viral oncoprotein antibody levels and challenge of requiring multi-modal imaging to detect clinical disease Open
View article: Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy
Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy Open
The integration of artificial intelligence (AI) and positron emission tomography (PET) imaging has the potential to become a powerful tool in drug discovery. This review aims to provide an overview of the current state of research and high…
View article: Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma Open
Concurrent administration pembrolizumab with chemotherapy in untreated classical Hodgkin lymphoma (CHL) has not previously been studied. To investigate this combination, we conducted a single arm study of concurrent pembrolizumab with AVD …
View article: 1472 Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy
1472 Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy Open
Background CD8 T-cells (CD8s) mediate the effects of most cancer immunotherapies. CD8s are typically assessed by biopsy which is inherently limited by sample availability, intratumoral and intrapatient heterogeneity, and difficulty with re…
View article: T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume Open
Figure 1: A: Progression-free survival; B: Scatter-plot demonstrating correlation of baseline TMTV with ctDNA levels; C: Spider-plot of ctDNA levels at various time points during the study color-coded by interim-PET results Introduction: W…
View article: Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
Pilot Study: PARP1 Imaging in Advanced Prostate Cancer Open
View article: The Development of <sup>18</sup>F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1
The Development of <sup>18</sup>F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1 Open
Fluorine 18 (18F) fluorthanatrace (18F-FTT) is a PET radiotracer for imaging poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1), an important target for a class of drugs known as PARP inhibitors, or PARPi. This…
View article: Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer Open
View article: Glypican-3–Targeted <sup>227</sup>Th <b>α</b>-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
Glypican-3–Targeted <sup>227</sup>Th <b>α</b>-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma Open
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide, with limited therapeutic options for advanced disease. Targeted α-therapy is an emerging class of targeted cancer therapy in which α-particle-emitt…
View article: Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases
Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases Open
Positron emission tomography (PET) is a quantitative molecular imaging modality increasingly used to study pulmonary disease processes and drug effects on those processes. The wide range of drugs and other entities that can be radiolabeled…
View article: How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?
How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer? Open
Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been appro…
View article: Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer
Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer Open
Introduction We hypothesized that FDG PET imaging during chemoradiation for unresectable non-small cell lung cancer (NSCLC) is prognostic for survival, and that tumor PET response is correlated with peripheral T-cell function. Methods 45 p…
View article: Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma
Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma Open
View article: Contributors
Contributors Open
View article: Imaging in Asthma
Imaging in Asthma Open
Asthma is a highly morbid and mortal disease. Despite initial improvements in treatment outcomes achieved with the introduction of bronchodilators and inhaled corticosteroids, no such improvements have been noted in the past decade. This l…
View article: Consensus Recommendations on the Use of<sup>18</sup>F-FDG PET/CT in Lung Disease
Consensus Recommendations on the Use of<sup>18</sup>F-FDG PET/CT in Lung Disease Open
PET with 18F-FDG has been increasingly applied, predominantly in the research setting, to study drug effects and pulmonary biology and to monitor disease progression and treatment outcomes in lung diseases that interfere with ga…
View article: Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial
Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial Open
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease without effective molecular markers of disease activity or treatment responses. Monocyte and interstitial macrophages that express the C-C mot…
View article: Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis
Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis Open
Idiopathic pulmonary fibrosis (IPF) is a progressive, inflammatory lung disease that is monitored clinically by measures of lung function, without effective molecular markers of disease activity or therapeutic efficacy. Lung immune cells a…
View article: Promising Advances for Imaging Lung Macrophage Recruitment
Promising Advances for Imaging Lung Macrophage Recruitment Open
View article: Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use
Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use Open
View article: An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants
An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants Open
Obliterative bronchiolitis (OB) is a poorly understood airway disease characterized by the generation of fibrotic bronchiolar occlusions. In the lung transplant setting, OB is a pathological manifestation of bronchiolitis obliterans syndro…